FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 803 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Selumetinib Approved by FDA to Treat Children with NF1 April 14, 2020 ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March March 14, 2025 Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated... November 9, 2022 Giving Myself the Most Time and Best Chance at Beating Cancer:... October 10, 2023 Load more HOT NEWS OncoArray Links Dozens of DNA Variants to Risk for Common Cancers Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... 10 Things About You That Change When You Lose Your Parents Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into...
